Pipeline
Our pipeline is built on one conserved adaptive repair biology that can be activated across multiple tissues. Lead asset leramistat, a first-in-class mitochondrial Complex I modulator (MCM), is in Phase 2 for musculoskeletal repair. Muscle is the cleanest first proof point; it’s highly regenerative and measurable, with a significant unmet clinical need. Additional MCMs and indications follow from the same platform logic.
Leramistat is an investigational first-in-class oral mitochondrial Complex I modulator designed to activate conserved adaptive repair biology. In Phase 2 development for musculoskeletal repair, it represents the lead validation of a platform that can restore the capacity of tissues to repair themselves. Prior clinical signals include bone protection, improved disability and fatigue, and reduced systemic inflammation. Preclinical data show restoration of muscle quality, in some models beyond younger baseline levels. Muscle is the cleanest first proof point for the adaptive repair platform — highly regenerative, measurable and high unmet need.
The same adaptive biology that drives muscle repair also operates in bone and in primary age-related sarcopenia and osteosarcopenia. Leramistat’s dual effects on muscle and bone position it for potential use across degenerative musculoskeletal conditions of ageing.
Additional indications (IPF and beyond) Leramistat supports adaptive repair in scarred lung tissue and holds FDA Fast Track and Orphan Drug Designation for idiopathic pulmonary fibrosis. The conserved nature of the adaptive programme opens further opportunities across chronic conditions where tissue repair has failed
Next-generation MCM MBS2687 is an orally available small-molecule mitochondrial Complex I modulator nominated as a development candidate. Designed with best-in-class potential within the MCM class. Part of the broader adaptive repair platform; indication to be defined as the programme advances.